Elif Yilmaz, M.D.

  • Internal Medicine - Hematology/Oncology
  • Stem Cell Transplantation
  • Cellular therapies for indolent and aggressive lymphomas

Biography

Elif Yilmaz, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in indolent and aggressive lymphomas, cellular therapies, and bone marrow transplant.

Dr. Yilmaz earned her medical degree at Istanbul University in Turkey. She completed a residency in internal medicine at Sinai Hospital of Baltimore and gained advanced training in hematology and medical oncology through fellowships at George Washington University and Georgetown University School of Medicine.

Certified by the American Board of Internal Medicine, she joined the UT Southwestern faculty in 2022.

Dr. Yilmaz is a member of the American Society of Hematology and the American Society of Clinical Oncology, among other professional organizations.

She has delivered several presentations and published several academic articles related to her areas of expertise.

Education & Training
  • Medical School - Cerrahpasa Medical School
  • Internship - Maimonides Medical Center (2015-2016), Internal Medicine
  • Residency - Sinai Hospital of Baltimore (2016-2019), Internal Medicine
  • Fellowship - George Washington University (2019-2021), Hematology Oncology
  • Fellowship - MedStar Georgetown University Hospital (2021-2022), Hematology Oncology
Professional Associations & Affiliations
  • American Society for Transplantation and Cellular Therapy
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Society of Hematologic Oncology
Honors & Awards
  • High Honor Student Award 2013, Educational Committee of Istanbul University Cerrahpasa Faculty of Medicine
Books & Publications
Research
  • Cellular therapies in the management of lymphoid malignancies
  • Immunodeficiency-associated lymphoproliferative disorders

Clinical Focus

  • Stem Cell Transplantation
  • Cellular therapies for indolent and aggressive lymphomas

See More